# An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

> **NCT02116803** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** dovitinib
- **DRUG:** fulvestrant

## Key facts

- **NCT ID:** NCT02116803
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-28
- **Primary completion:** 2016-11-28
- **Final completion:** 2016-11-28
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02116803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02116803, "An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02116803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*